Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

U S Physical Therapy (USPH) Cash from Investing Activities (2016 - 2025)

U S Physical Therapy's Cash from Investing Activities history spans 12 years, with the latest figure at -$8.4 million for Q4 2023.

  • For Q4 2023, Cash from Investing Activities rose 80.61% year-over-year to -$8.4 million; the TTM value through Dec 2023 reached -$45.0 million, up 44.61%, while the annual FY2025 figure was -$36.7 million, 75.43% up from the prior year.
  • Cash from Investing Activities for Q4 2023 was -$8.4 million at U S Physical Therapy, up from -$16.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$2.2 million in Q2 2020 and bottomed at -$79.9 million in Q4 2021.
  • The 5-year median for Cash from Investing Activities is -$12.9 million (2021), against an average of -$17.0 million.
  • The largest annual shift saw Cash from Investing Activities surged 89.54% in 2020 before it tumbled 835.62% in 2021.
  • A 5-year view of Cash from Investing Activities shows it stood at -$6.0 million in 2019, then crashed by 369.28% to -$28.3 million in 2020, then crashed by 182.37% to -$79.9 million in 2021, then surged by 45.68% to -$43.4 million in 2022, then soared by 80.61% to -$8.4 million in 2023.
  • Per Business Quant, the three most recent readings for USPH's Cash from Investing Activities are -$8.4 million (Q4 2023), -$16.9 million (Q3 2023), and -$7.0 million (Q2 2023).